Log In
BCIQ
Print this Print this
 

ADVM-043 (formerly ANN-001)

  Manage Alerts
Collapse Summary General Information
Company Weill Cornell Medical College
DescriptionAAV delivering alpha-1 antitrypsin (AAT; A1AT; SERPINA1)
Molecular Target Alpha-1 antitrypsin (AAT) (A1AT) (SERPINA1)
Mechanism of Action 
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationAlpha-antitrypsin (AAT) deficiency
Indication DetailsTreat alpha 1-antitrypsin (AAT) deficiency
Regulatory Designation
PartnerAdverum Biotechnologies Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$105.6M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/12/2016

$105.6M

0

0

Get a free BioCentury trial today